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Abstract
Objective: To describe and identify risk factors of maternal 
and perinatal outcome of COVID-19 in pregnant women.
Methods: Literature search was conducted on MEDLINE and 
Google Scholar databases for articles published in December 
2020 to January 2021. Keywords used includes ‘COVID-19’, 
‘pregnant women’, ‘maternal outcome’ and ‘fetal outcome.’ 
Critical appraisal and selection were conducted to identify 
articles that fulfill inclusion criteria. The selected articles were 
analyzed thematically to answer the research questions.
Results: Literature search yielded 124 articles with 11 
included in final analysis. The results showed low to moderate 
risk of maternal and perinatal adverse outcomes, including 
low risks for maternal and perinatal mortality coupled with 
moderate risk for maternal ICU admission and preterm 
birth with NICU admission for the newborn. Higher risk was 
observed for pregnant women with symptomatic COVID-19 
infection, which points to the necessity for awareness of the 
risk and targeted early detection efforts.
Conclusions: There are low risk for adverse maternal and 
perinatal outcomes, including mortality and ICU/NICU 
admission, associated with COVID-19 infection in pregnant 
women. Risk factors for adverse outcomes included pregnant 
women with symptomatic COVID-19 infection.
Keywords: COVID-19, ICU, maternal mortality, NICU, 
perinatal mortality, preterm birth.
Abstrak
Tujuan: Mendeskripsikan dan mengidentifikasi faktor risiko 
luaran maternal dan perinatal COVID-19 pada ibu hamil.
Metode: Penelusuran literatur dilakukan di database 
MEDLINE dan Google Scholar untuk artikel yang diterbitkan 
pada Desember 2020 hingga Januari 2021. Kata kunci yang 
digunakan meliputi 'COVID-19', 'wanita hamil', 'keluaran 
ibu' dan 'hasil janin'. Penilaian dan seleksi kritis dilakukan 
untuk mengidentifikasi artikel yang memenuhi kriteria 
inklusi. Artikel yang dipilih dianalisis secara tematis untuk 
menjawab pertanyaan penelitian.
Hasil: Penelusuran literatur menghasilkan 124 artikel 
dengan 11 termasuk dalam analisis akhir. Hasil penelitian 
menunjukkan risiko rendah hingga sedang untuk luaran 
buruk maternal dan perinatal, termasuk risiko rendah 
untuk kematian maternal dan perinatal ditambah dengan 
risiko sedang untuk masuk ICU ibu dan kelahiran prematur 
dengan masuk NICU untuk bayi baru lahir. Risiko yang lebih 
tinggi diamati untuk wanita hamil dengan infeksi COVID-19 
bergejala, yang menunjukkan perlunya kesadaran akan 
risiko dan upaya deteksi dini yang ditargetkan.
Kesimpulan: Terdapat risiko rendah untuk laran buruk 
maternal dan perinatal, termasuk kematian dan rawat inap 
di ICU/NICU, terkait dengan infeksi COVID-19 pada wanita 
hamil. Faktor risiko untuk luaran buruk adalah wanita hamil 
dengan gejala infeksi COVID-19.
Kata kunci: COVID-19, ICU, kelahiran preterm, mortalitas 
maternal, mortalitas perinatal, NICU.
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INTRODUCTION
COVID-19 has infected over 100 million 
people worldwide, causing over 2 million deaths. 
In many countries, its spread is uncontrolled with 
most nations in the world reporting community 
transmissions.1 In such countries, every members 
of community are considered at risk population, 
regardless of known contact to an infected 
person, including pregnant women.2
There has been no definitive data on the extent 
pregnant women make up COVID-19 confirmed 
cases worldwide. An early screening study in New 
York, United States, found 13.5% asymptomatic 
infections and 1.9% symptomatic infections from 
215 screened obstetric patients presenting for 
delivery.3 However, an epidemiological update 
by Pan-American Health Organization (PAHO) 
in September 2020 presented much lower rate 
with 60,458 cases in pregnant women from 
over 6 million cumulative cases, a much lower 
proportion.4
Nevertheless, infection of a novel virus to 
pregnant women population opens up various 
unknown risks. The most immediate being to the 
pregnancy, maternal, and perinatal outcomes. 
Reviews on early reports of COVID-19 impacts 
on pregnancy showed differing results. One 
review reported over 90% pregnant women 
with COVID-19 required caesarean sections with 
10.7% fetal distress and 21.3% preterm birth.5 
Another reported much bleaker situation with 
over 60% fetal distress.6
These early reviews relied much on case 
reports and case series, each reporting few cases. 
As demonstrated by aforementioned PAHO 
report, COVID-19 cases in pregnant women were 
quite rare. As situation developed, more reports 
emerged which included larger sample size 
and more accurately described the outcome of 
COVID-19 infection among pregnant women.
In accordance to these new emerging 
evidences, we aimed to review it to make a 
more cohesive picture. Our primary objective in 
this review is to describe maternal and perinatal 
outcome of COVID-19 infection in pregnancy. 
Meanwhile, our secondary objective is to describe 
risk factors for adverse outcomes for pregnant 
women with COVID-19 infection.
METHODS
We conducted a review on open-access 
literatures on COVID-19 infection in pregnant 
women. Literature search was conducted on 
MEDLINE and Google Scholar databases from 
December 2020 to January 2021 using keywords 
that included ‘COVID-19’, ‘pregnant women’, 
‘maternal outcome’ and ‘fetal outcome.’ Results 
was limited to those published after May 1st 
2020. 
For analysis, we included descriptive and 
analytic studies describing maternal and fetal 
outcome of confirmed COVID-19 infection 
during pregnancy. We excluded case reports, 
case series, and studies with sample size less than 
50 to give more accurate picture of the situation. 
We also excluded studies which conflated the 
statistics of confirmed and suspected COVID-19 
cases among pregnant women.
Variables of interest for maternal outcome 
included ICU admission and maternal mortality 
rate. Meanwhile, variables of interest pregnancy 
and perinatal outcomes included percentage of 
live birth, preterm birth, NICU admission, and 
mortality. Included studies do not have to report 
on all these variables. Report one at least one 
variable was sufficient for inclusion.
Studies were appraised for quality before 
inclusion and analysis. Quality appraisal was 
conducted using CASP (Critical Appraisal Skills 
Programme) Checklist for appropriate study 
design reported. The checklist included questions 
on research questions, methodology, and analysis 
technique employed to assess validity of results.
Data extraction was conducted with pre-
piloted forms by both authors independently 
of each other. Extracted data included date 
of publication, study design, sample size, and 
description of variables of interest. The results 
were compared between the two authors and 
duplicates were reconciled. Inclusion or exclusion 
was discussed and agreed upon by all authors 
before effected.
RESULTS
As visible in Figure 1, literature search identified 
124 studies, of which 77 was immediately 
excluded due to having ‘review’, ‘case report’, 
or ‘case series’ on the title and/or abstract. We 
reviewed the abstract for the remaining 47 
studies and excluded 19 more for describing case 
report or case series results. From 28 studies with 
underwent data extraction, another 17 studies 
were excluded for having sample size less than 50 
or results that conflate confirmed and suspected 
COVID-19 cases. The remaining 11 studies was 




There are variations between included studies, 
based on design and inclusion criteria. By 
design, there were 4 cohorts, either prospective 
or retrospective, 5 retrospective studies, either 
analytic or descriptive, and 2 case-control designs.
Inclusion criteria varies, even between studies 
with similar design. Some analytic studies 
included both confirmed, suspected, and/or non-
COVID-19 cases,7–9 as well as pregnant and non-
pregnant COVID-19 cases.10 For these studies, 
we only extracted data for pregnant women with 
confirmed COVID-19 cohort or group.
Figure 1. Literature search and selection diagram.
Table 1. Characteristics of included studies




















388 pregnant women with 
confirmed COVID-19, 266 
of which completed their 
pregnancy
242 women who gave live 
birth while having confirmed 
COVID-19
68 pregnant women with 
confirmed COVID-19, 56 
of which completed their 
pregnancy
252 pregnant women with 
confirmed COVID-19 who 
completed their pregnancy
185 pregnant women with 
confirmed COVID-19, 169 
of which completed their 
pregnancy
Risk factors associated with adverse 
fetal outcomes in pregnancies 
affected by Coronavirus disease 2019 
(COVID-19): a secondary analysis of the 
WAPM study on COVID-19
Maternal, Perinatal and Neonatal 
Outcomes With COVID-19: A 
Multicenter Study of 242 Pregnancies 
and Their 248 Infant Newborns During 
Their First Month of Life
The Relationship between Status at 
Presentation and Outcomes among 
Pregnant Women with COVID-19
Pregnancy Outcomes Among Women 
With and Without Severe Acute 
Respiratory Syndrome Coronavirus 2 
Infection
Maternal and perinatal characteristics 
and outcomes of pregnancies 
complicated with COVID-19 in Kuwait
Author Design Ref.Sample SizeTitle























598 pregnant women with 
confirmed COVID-19, 458 
of which completed their 
pregnancy
4,442 completed pregnancy 
with confirmed COVID-19
141 completed pregnancy with 
confirmed COVID-19
65 pregnant women with 
confirmed COVID-19, 50 of 
which gave live birth
83 pregnant women with 
confirmed COVID-19
65 pregnant women who 
gave live birth with confirmed 
COVID-19
Characteristics and Maternal and Birth 
Outcomes of Hospitalized Pregnant 
Women with Laboratory-Confirmed 
COVID-19 — COVID-NET, 13 States, 
March 1–August 22, 2020
Birth and Infant Outcomes Following 
Laboratory-Confirmed SARS-CoV-2 
Infection in Pregnancy — SET-NET, 16 
Jurisdictions, March 29–October 14, 
2020
Impact of the Coronavirus Infection in 
Pregnancy: A Preliminary Study of 141 
Patients
Coronavirus disease 2019 in pregnant 
women: a report based on 116 cases
Are clinical outcomes worse for 
pregnant women at < 20 weeks’ 
gestation infected with coronavirus 
disease 2019? A multicenter case-
control study with propensity score 
matching
Pregnant women with COVID-19 and 
risk of adverse birth outcomes and 
maternal-fetal vertical transmission: 
a population-based cohort study in 
Wuhan, China
Due to different in design and inclusion 
criteria, there were also difference in outcome 
of observation reported between included 
studies. Most studies included pregnant 
women with COVID-19 regardless of pregnancy 
completion.11,13–16 Some studies included only 
women who give live birth with concurrent 
COVID-19 infection, thus did not report 
incidences of adverse pregnancy outcomes such 
as miscarriage or stillbirths.10,12,17
As much as 7 studies reported both variables 
of interest on maternal outcome, namely 
ICU admission and mortality, while 2 studies 
reported only maternal mortality rate. There are 
wide variation in reported ICU admission rate 
for pregnant women with confirmed COVID-19, 
ranging from 1.1% 14 to 17.6%.13
Accounting for sample size variation, however, 
the reports indicate there was a cumulative of 
125 ICU admission from 1,629 observed pregnant 
women in the seven studies that reported this 
variable.8,10–15 This translates to an ICU admission 
rate of 7.67%.
Meanwhile, from 9 studies which reported 
maternal mortality rate, 6 reported no 
deaths.7,8,10,13,14 The others reported very low 
mortality rate, ranging from 0.3%15 to 2.12%.9 
Overall, there was only 9 mortality events from 
2,022 observed pregnant women observed 
by studies that reported this variable.7–15 This 
translates to maternal mortality rate of 0.5%.
Almost all included studies reported one 
or both of rate of live and preterm births from 
observed pregnant women with COVID-19. Most 
reported high live birth rate, in excess of 95%. 
Table 2. ICU Admission and Maternal Mortality Rate 
Reported in Included 
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The lowest reported live birth rate was 94.4%11 
while the highest was 99.3%.16
Several included studies reported comparison 
between pregnant women with Some included 
studies reported comparison between pregnant 
women with confirmed COVID-19 with outside 
Some of these studies included multiple 
pregnancies, which leads to the number of 
live births to exceed the number of observed 
mothers. A significant proportion of these births 
was preterm, however, with preterm births 
making up around 20% of live births. The lowest 
reported proportion of preterm births was 11%7 
and the highest was 32%.8 From 5,439 observed 
live births with known gestational age, there was 
773 preterm infants, translating to preterm birth 
rate of 14.2%.
Meanwhile, there was 8 studies who followed 
up on the newborn and reported either one or 
both of NICU admission and perinatal mortality. 
Similar to ICU admission for pregnant women, 
there was wide variation of NICU admission rate 
among newborn of these women. The lowest 
reported NICU admission rate was 3%14 while the 
highest was ten-times that at 34%.8 Mortality was 
low, however, with most studies reported zero 
death and the highest reported 2% perinatal 
mortality rate.8,11
groups, which may include pregnant women 
with suspected, but not confirmed, COVID-19 8 or 
pregnant women without COVID-19.7,9,10,17 Others 
reported comparison between two subgroups 
of symptomatic and asymptomatic pregnant 
women with COVID-19.13,15,16
Comparison of maternal outcomes between 
confirmed and suspected groups showed no 
difference in mortality rate. However, pregnant 
women with confirmed COVID-19 were more 
likely to be admitted to ICU compared to 
suspected group (9.2% vs 3.9%). However, 
no statistical tests were conducted to see the 
significance of this difference.8
Nayak et al. reported higher risk of maternal 
mortality in COVID-19 confirmed pregnant 
women (2.12% vs 0.95%) although the difference 
was not statistically significant (p > 0.05).9 
However, Badr et al. reported higher risk of ICU 
admission for pregnant women with confirmed 
COVID-19.10 Meanwhile, conflicting evidence 
was presented on risk of preterm birth between 
the two groups, with one study reporting no 
statistically significant difference7 while another 
reporting significant increased risk of preterm 
birth in confirmed group with OR of 3.71 (95% CI 
1.70 – 8.03).17
Results on comparison between symptomatic 
and asymptomatic confirmed COVID-19 pregnant 
women painted a more cohesive picture. Women 
with symptomatic confirmed COVID-19 was more 
at risk for ICU admission necessitating ventilation 
support (26.1% vs 0%)13 and mortality (0.7% vs 
0%).15 Women with symptomatic COVID-19 was 
also less likely to give live birth compared to their 
asymptomatic counterparts (95% vs 99.1%).15 
Meanwhile, conflicting evidence was reported on 
risk of preterm birth with Delahoy et al. reporting 
increased risk among symptomatic group while 
Woodworth et al. reporting no difference.15,16
DISCUSSION
Our review result showed relatively low risk 
of adverse outcomes for pregnant women with 
concurrent COVID-19 infection. While there 
was moderate risk of ICU admission, there was 
relatively low risk of maternal mortality. Similarly, 
there was high chance of successful pregnancy 
with live birth although it was accompanied with 
moderate risk of preterm pregnancy and NICU 
admission. Perinatal mortality rate, however, was 
low.
This result was not much different from early 
Table 3. Pregnancy outcomes reported in included studies
Table 4. Perinatal Outcomes Reported in Included Studies






















































































Vol 9. No 4. October 2021 Maternal and Perinatal Outcomes 227
reviews, although early reviews tend to report 
higher proportion of mortality or other adverse 
events. One early review reported preterm birth 
rate of 63.8% and NICU admission rate of 76.92%.6 
Another review reported 2 maternal mortality 
out of 20 pregnant women reviewed from case 
reports, a mortality rate of 10%.18 Another early 
review, however, reported similar results to ours 
with 21.3% preterm birth rate and 1.2% perinatal 
mortality.5
The similarity of these early reviews, however, 
was the low number of cases included in the 
review. As report by PAHO showed, pregnant 
women with COVID-19 was not that frequent.4 
Thus these early reviews reported results based 
on under 100 cases based mostly on case reports 
and case series.5,6,18 Some of these reviews also 
included suspected but not confirmed COVID-19 
cases in the review.6
Later reviews and meta-analyses involving 
more observed reported much lower rate of 
adverse event however, similar to our results. 
Two large reviews published in the latter half of 
2020 found maternal mortality rate of 1.7% and 
0.6%, similar to our findings.19,20 Similar lower rate 
for other maternal and perinatal outcomes was 
also reported by other later reviews.
The reasoning was that earlier case reports 
and case series was made in the period when 
many things was unknown about COVID-19, 
such as lack of understanding of the prevalence 
of asymptomatic cases. This cause many reviews 
to include disproportionately more symptomatic 
cases, increasing risk of adverse events in their 
cohort.21
Our results also imply the highest risk of 
adverse event was among pregnant women with 
symptomatic COVID-19 infection. This point to 
the probability that the viral infection itself was not 
the cause of adverse event, unlike some other viral 
infection.22 Instead, inflammation, its associated 
symptoms, and potential exacerbation was the 
cause for the majority of adverse outcomes such 
as necessity for induction or caesarean section, 
preterm delivery, and perinatal complications.21
The clinical implication from our findings was 
the necessity to be aware of the risk of adverse 
outcomes when facing cases of pregnant women 
with concurrent COVID-19 infection. The risk 
would be higher in cases of symptomatic cases. 
As such, due preparation should be made, 
such as close monitoring of maternal and fetal 
conditions, as well as preparation for ICU and 
NICU admission.
Meanwhile, our result also points to a 
possible public health intervention in the form 
of targeted screening for symptomatic women 
during antenatal care in places where community 
transmission was common. Awareness for this 
necessary action should be emphasized in 
outpatient antenatal care facility which may 
not have in-house laboratory. Earlier detection 
would allow for closer monitoring and better 
preparation, hopefully improving outcomes. 
However, more study should be conducted on 
the cost-effectiveness of the measure.
While this study may provide updated picture 
of COVID-19 infection during pregnancy, it comes 
with its own shortcomings. Our literature search 
which relied on open-access databases may 
causes less than comprehensive results. As such, 
there may be some studies fulfilling inclusion 
criteria that was not included in this study.
CONCLUSION
Our results showed relatively low occurrences 
of adverse maternal and perinatal outcomes 
for pregnant women with concurrent COVID-19 
infection. Increased risk was observed 
in symptomatic infections compared to 
asymptomatic ones. Awareness of the potential 
risk should be coupled with attempts for targeted 
early detection during antenatal care.
REFERENCES
1. World Health Organization. COVID-19 Weekly 




2. Byambasuren O, Cardona M, Bell K, Clark J, McLaws 
M-L, Glasziou P. Estimating the extent of asymptomatic 
COVID-19 and its potential for community transmission: 
Systematic review and meta-analysis. Off J Assoc Med 
Microbiol Infect Dis Canada. 2020;5(4):223–34. 
3. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal 
Screening for SARS-CoV-2 in Women Admitted for 
Delivery. N Engl J Med. 2020;382(22):2163–4. 
4. PAHO. Epidemiological Update Coronavirus disease 
[Internet]. 2020. Available from: https://www.paho.org/
en/covid-19-situation-reports
5. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 
2019 (COVID-19) and pregnancy: a systematic review. 
J Matern Neonatal Med [Internet]. 2020;0(0):1–4. 
Available from: https://doi.org/10.1080/14767058.202
0.1759541
6. Smith V, Seo D, Warty R, Payne O, Salih M, Chin KL, 
et al. Maternal and neonatal outcomes associated 
with COVID-19 infection: A systematic review. PLoS 
One [Internet]. 2020;15(6):1–13. Available from: http://
dx.doi.org/10.1371/journal.pone.0234187
228 Pramana, Wirawan, Astiti and Kaspan
Indones J
Obstet Gynecol
7. Adhikari EH, Moreno W, Zofkie AC, MacDonald L, 
McIntire DD, Collins RRJ, et al. Pregnancy Outcomes 
Among Women With and Without Severe Acute 
Respiratory Syndrome Coronavirus 2 Infection. JAMA 
Netw Open. 2020;3(11):e2029256. 
8. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus 
disease 2019 in pregnant women: a report based on 116 
cases. Am J Obstet Gynecol [Internet]. 2020;223(1):111.
e1-111.e14. Available from: https://doi.org/10.1016/j.
ajog.2020.04.014
9. Nayak AH, Kapote DS, Fonseca M, Chavan N, Mayekar R, 
Sarmalkar M, et al. Impact of the Coronavirus Infection 
in Pregnancy: A Preliminary Study of 141 Patients. J 
Obstet Gynecol India [Internet]. 2020;70(4):256–61. 
Available from: https://doi.org/10.1007/s13224-020-
01335-3
10. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, 
El Hachem L, et al. Are clinical outcomes worse for 
pregnant women at ≥20 weeks’ gestation infected with 
coronavirus disease 2019? A multicenter case-control 
study with propensity score matching. Am J Obstet 
Gynecol. 2020;223(5):764–8. 
11. D. DM, C. S, G. S, A. G, A. G, J. Y, et al. Risk Factors 
Associated with Adverse Fetal Outcomes in Pregnancies 
Affected by Coronavirus Disease 2019 (COVID-19): A 
Secondary Analysis of the WAPM study on COVID-19. 
J Perinat Med [Internet]. 2020;48(9):950–8. Available 
from: http://www.degruyter.com/view/j/jpme
12. Marín Gabriel MA, Reyne Vergeli M, Caserío Carbonero 
S, Sole L, Carrizosa Molina T, Rivero Calle I, et al. 
Maternal, Perinatal and Neonatal Outcomes with 
COVID-19: A Multicenter Study of 242 Pregnancies and 
Their 248 Infant Newborns during Their First Month of 
Life. Pediatr Infect Dis J. 2020;39(12):E393–7. 
13. London V, McLaren R, Atallah F, Cepeda C, McCalla 
S, Fisher N, et al. The Relationship between Status at 
Presentation and Outcomes among Pregnant Women 
with COVID-19. Am J Perinatol. 2020;37(1):991–4. 
14. Ayed A, Embaireeg A, Benawath A, Al-Fouzan W, 
Hammoud M, Al-Hathal M, et al. Maternal and 
perinatal characteristics and outcomes of pregnancies 
complicated with COVID-19 in Kuwait. medRxiv. 
2020;2:1–9. 
15. Delahoy MJ, Whitaker M, Chai SJ, Daily Kirley P, Alden 
N, Kawasaki B, et al. Morbidity and Mortality Weekly 
Report Characteristics and Maternal and Birth Outcomes 
of Hospitalized Pregnant Women with Laboratory-
Confirmed COVID-19-COVID-NET, 13 States. Morbitity 
Mortal Wkly Rep. 2020;69(38):1347–54. 
16. Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang 
RR, Oduyebo T, et al. Birth and Infant Outcomes 
Following Laboratory-Confirmed SARS-CoV-2 Infection 
in Pregnancy — SET-NET, 16 Jurisdictions, March 29–
October 14, 2020. MMWR Morb Mortal Wkly Rep. 
2020;69(44):1635–40. 
17. Yang R, Mei H, Zheng T, Fu Q, Zhang Y, Buka S, et al. 
Pregnant women with COVID-19 and risk of adverse 
birth outcomes and maternal-fetal vertical transmission: 
a population-based cohort study in Wuhan, China. BMC 
Med. 2020;18(1):1–7. 
18. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect 
of coronavirus disease 2019 (COVID-19) on maternal, 
perinatal and neonatal outcome: systematic review. 
Ultrasound Obstet Gynecol. 2020;56(1):15–27. 
19. Khalil A, Kalafat E, Benlioglu C, O’Brien P, Morris E, 
Draycott T, et al. SARS-CoV-2 infection in pregnancy: A 
systematic review and meta-analysis of clinical features 
and pregnancy outcomes. EClinicalMedicine [Internet]. 
2020;25(December 2019):100446. Available from: 
https://doi.org/10.1016/j.eclinm.2020.100446
20. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew 
T, et al. Clinical manifestations, risk factors, and maternal 
and perinatal outcomes of coronavirus disease 2019 in 
pregnancy: Living systematic review and meta-analysis. 
BMJ. 2020;370. 
21. Papapanou M, Papaioannou M, Petta A, Routsi E, 
Farmaki M, Vlahos N, et al. Maternal and neonatal 
characteristics and outcomes of covid-19 in pregnancy: 
An overview of systematic reviews. Int J Environ Res 
Public Health. 2021;18(2):1–20. 
22. Racicot K, Mor G. Risks associated with viral infections 
during pregnancy. J Clin Invest. 2017;127(5):1591–9. 
Vol 9. No 4. October 2021 Maternal and Perinatal Outcomes 229
